Jasper Therapeutics (JSPR) to Release Quarterly Earnings on Monday

Jasper Therapeutics (NASDAQ:JSPR) is expected to announce its earnings results before the market opens on Monday, March 3rd. Analysts expect the company to announce earnings of ($1.20) per share for the quarter.

Jasper Therapeutics Trading Down 3.1 %

Shares of NASDAQ JSPR opened at $5.97 on Monday. Jasper Therapeutics has a 12 month low of $4.55 and a 12 month high of $31.01. The firm has a market capitalization of $89.52 million, a PE ratio of -1.26 and a beta of 2.11. The firm has a fifty day simple moving average of $11.23 and a two-hundred day simple moving average of $17.14.

Analysts Set New Price Targets

Several brokerages have recently issued reports on JSPR. JMP Securities reissued a “market outperform” rating and issued a $70.00 target price on shares of Jasper Therapeutics in a research report on Monday, January 6th. BMO Capital Markets initiated coverage on Jasper Therapeutics in a research report on Friday, December 6th. They set an “outperform” rating and a $63.00 price objective for the company. UBS Group began coverage on shares of Jasper Therapeutics in a research report on Thursday, February 13th. They issued a “buy” rating and a $38.00 target price on the stock. Royal Bank of Canada lowered their price target on shares of Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating for the company in a research report on Thursday, January 9th. Finally, HC Wainwright dropped their price objective on shares of Jasper Therapeutics from $60.00 to $40.00 and set a “buy” rating on the stock in a research note on Friday, January 10th. Eleven investment analysts have rated the stock with a buy rating, According to MarketBeat, Jasper Therapeutics currently has an average rating of “Buy” and a consensus price target of $64.44.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.